Blood Test Detects Alzheimer's 15 Years Early, Offering Hope for Prevention

A blood test that can spot Alzheimer's disease a decade and a half before a person shows any symptoms has moved from laboratory promise into clinical reality. Researchers have now confirmed that the test—already available commercially—performs as well as the invasive procedures doctors currently rely on, opening a path toward catching the disease when intervention might actually work.

The test hunts for a protein called p-tau217 in the bloodstream. This marker begins to accumulate years before the cognitive decline that defines Alzheimer's takes hold. In an eight-year trial involving 786 people, the assay detected tau buildup with 97% accuracy, matching the precision of expensive brain imaging and lumbar punctures—procedures that require either radiation exposure or a needle inserted into the spinal cord. For the first time, clinicians could tell patients whether their risk was high, medium, or low without subjecting them to those more invasive methods.

The commercial version, called the ALZpath pTau217 assay, is already in use across multiple laboratories worldwide for research purposes. It is expected to transition to clinical use soon, with an estimated cost between €180 and €460 per test. Results would arrive within days rather than the months or years currently required to navigate the diagnostic pathway. The speed matters. Ireland alone has 64,000 people living with dementia today; by 2045, that figure is projected to climb to 150,000. Early detection could reshape how the disease is managed across the population.

The real significance lies not in the test itself but in what comes next. Two new drugs—donanemab and lecanemab—show promise in slowing cognitive decline, but only if administered early, before too much damage accumulates. A simple blood test that identifies people at risk years in advance creates the possibility of treatment before symptoms emerge. Professor David Curtis from University College London framed it plainly: the test is half the solution. The other half is having drugs that actually work. When both pieces align, the implications could be substantial.

Experts are already imagining a future where everyone over 50 receives routine screening every few years, much as people now get cholesterol checks. Those identified as high-risk could begin treatment while their brains are still largely intact. The combination of early detection and effective medication could reshape individual outcomes and ease the burden on healthcare systems facing a wave of dementia cases. Researchers from the University of Gothenburg, who co-authored the study, called it an instrumental finding that clears the way for blood-based diagnosis to replace more cumbersome methods.

Yet questions remain. Dr. Richard Oakley from the UK's Alzheimer's Society welcomed the advance but noted that more research across diverse populations is needed to ensure the test performs equally well across different communities. The test is currently approved for research use only. The transition to routine clinical practice will depend on regulatory approval, integration into healthcare systems, and—crucially—the arrival of treatments effective enough to justify screening millions of people who might never develop symptoms. For now, the blood test represents a significant step: a way to see the disease coming, years before it announces itself.